A Value-Based Medicine Comparison of Interventions for Subfoveal Neovascular Macular Degeneration
- 30 June 2007
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 114 (6), 1170-1178
- https://doi.org/10.1016/j.ophtha.2006.09.019
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The Cost-Utility of Photodynamic Therapy in Eyes With Neovascular Macular Degeneration—A Value-Based Reappraisal With 5-Year DataAmerican Journal of Ophthalmology, 2005
- Pegaptanib for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2004
- Fluorescein angiographic lesion type frequency in neovascular Age-Related macular degenerationOphthalmology, 2004
- Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1American Journal of Ophthalmology, 2003
- Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye studyOphthalmology, 2002
- Validity of the time trade-off and standard gamble methods of utility assessment in retinal patientsBritish Journal of Ophthalmology, 2002
- Quality of life and systemic comorbidities in patients with ophthalmic diseaseBritish Journal of Ophthalmology, 2002
- Utility values associated with blindness in an adult populationBritish Journal of Ophthalmology, 2001
- Utility Values and Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2000
- Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and MedicineJama-Journal Of The American Medical Association, 1996